Efficacy of Ofloxacin vs Cefazolin and Tobramycin in the Therapy for Bacterial Keratitis: Report From the Bacterial Keratitis Study Research Group

Archives of Ophthalmology

Volumn 113, Issue 10, 1995, Pages 1257-1265

  O'brien, Terrence P ^a   Maguire, Maureen G ^a   Fink, Nancy E ^a   Alfonso, Eduardo ^a   Mcdonnell, Peter ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; OFLOXACIN; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EYE IRRITATION; FEMALE; HUMAN; INFECTION CONTROL; KERATITIS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CEFAZOLIN; CEPHALOSPORINS; CORNEA; CORNEAL ULCER; DOUBLE-BLIND METHOD; DRUG EVALUATION; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 0029121361     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archopht.1995.01100100045026     Document Type: Article

References (32)

1. Jones DB. Decision-making in management of microbial keratitis. Ophthalmology. 1981;88:814-820.
2. Pepose JS, Wilhelmus KR. Divergent approaches to the management of corneal ulcers. Am J Ophthalmol. 1992;114:630-632.
3. Baum JL, Jones DB. Initial therapy of suspected microbial corneal ulcers, I: broad antibiotic therapy based on prevalence of organisms. II: specific antibiotic therapy based on corneal smears. Surv Ophthalmol. 1979;24:97-116.
4. Jones DB. A plan for antimicrobial therapy in bacterial keratitis. Trans Am Acad Ophthalmol Otolaryngol. 1974;79:94-103.
5. Wilhelmus KR, Liesegang TK, Osato MS, Jones DB. Cumitech 13A: Laboratory Diagnosis of Ocular Infections. Washington, DC: American Society for Microbiology Press; 1994.
6. Jones DB. Early diagnosis and therapy of bacterial corneal ulcers. Int Ophthalmol Clin. 1973;13:1-29.
7. McDonnell PJ, Nobe J, Gauderman WJ, Lee P, Aiello A, Trousdale M. Community care of corneal ulcers. Am J Ophthalmol. 1992;114:531-538.
8. Poggio ED, Glyn RJ, Schein OD, et al. The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. N Engl J Med. 1989;321:779-783.
9. Baum JL, Barza M, Weinstein L. Preferred routes of antibiotic administration and treatment of bacterial ulcers of the cornea. Int Ophthalmol Clin. 1973;13:31-37.
10. Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectrum of activity in vitro. Antimicrob Agents Chemother. 1985;28:581-586.
11. Norris S, Mandell G. The quinolones: history and overview. In: Androile VT, ed. The Quinolones. Orlando, Fla: Academic Press Inc; 1988:1-22.
12. O'Brien TP, Sawusch M, Dick JD, Gottsch JD. Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits. Arch Ophthalmol. 1988;106:1444-1446.
13. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991;112 (suppl S):29S-33S.
14. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for the treatment of bacterial keratitis. Am J Ophthalmol. 1991;112(suppl S): 34S-47S.
15. Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al. 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. Arch Ophthalmol. 1993;111:1210-1218.
16. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep. 1978;62:1037-1040.
17. Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc. 1963;75:947-951.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;2:187-220.
20. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
21. Liesegang TJ. Bacterial and fungal keratitis. In: Kaufman HE, ed. Cornea. New York, NY: Churchill Livingstone Inc; 1988:217-270.
22. Roussel TJ, Osato MS, Robinson NM, et al. Resistant Pseudomonas keratitis. J Ocul Ther Surg. 1984;3:136-138.
23. Campoli-Richards DM, Monk JP, Price A, et al. Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1988;35:373-447.
24. Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985;28:581-586.
25. Elipooulos GM, Gardella A, Moellering RC. In vitro activity of ciprofloxacin, a new carboxyquinolone antimicrobial agent. Antimicrob Agents Chemother. 1984;25:331-335.
26. Kayser FH, Novak J. In vitro activity of ciprofloxacin against gram-positive bacteria: an overview. Am J Med. 1987;82(suppl 4A):33-39.
27. Barry Al, Jones RN. In vitro activity of ciprofloxacin against gram-positive cocci. Am J Med. 1987;82(suppl 4A):27-32.
28. Chin NX, Neu HC. Post-antibiotic supressive effect of ciprofloxacin against gram-negative bacteria. Am J Med. 1987;82(suppl 4A);58-62.
29. Smith SM, Eng RH. Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1985;27:688-691.
30. Liesegang TJ, Forster RF. Spectrum of microbial keratitis in south Florida. Am J Ophthalmol. 1980;90:38-47.
31. Musch DC, Sugar A, Meyer RF. Demographic and predisposing factors in corneal ulceration. Arch Ophthalmol. 1983;101:1545-1548.
32. Neuman M, Esanu A. Gaps and perspective of new fluoroquinolones. Drugs Exp Clin Res. 1988;14:385-391.